SKBA Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$224K Buy
+3,700
New +$216K 0.03% 79
2025
Q2
Sell
-3,700
Closed -$226K 85
2025
Q1
$226K Hold
3,700
0.03% 85
2024
Q4
$209K Buy
+3,700
New +$207K 0.03% 76
2024
Q2
Sell
-3,700
Closed -$201K 75
2024
Q1
$201K Buy
+3,700
New +$188K 0.03% 75
2023
Q4
Sell
-3,700
Closed -$215K 78
2023
Q3
$215K Hold
3,700
0.04% 75
2023
Q2
$237K Hold
3,700
0.04% 75
2023
Q1
$256K Hold
3,700
0.05% 72
2022
Q4
$266K Hold
3,700
0.05% 68
2022
Q3
$263K Hold
3,700
0.06% 67
2022
Q2
$285K Hold
3,700
0.06% 67
2022
Q1
$270K Sell
3,700
-500
-12% -$33.6K 0.05% 74
2021
Q4
$262K Hold
4,200
0.05% 77
2021
Q3
$249K Hold
4,200
0.05% 74
2021
Q2
$281K Hold
4,200
0.06% 70
2021
Q1
$265K Buy
4,200
+500
+14% +$31.1K 0.04% 72
2020
Q4
$230K Buy
+3,700
New +$228K 0.04% 71

Other funds holding BMY

SKBA Capital Management's BMY Position: Q1 2026 in Review

SKBA Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 3,700 shares worth $224K. The stake represents 0.03% of the portfolio and ranks #79 among its holdings. This is a return to the name: SKBA Capital Management previously reported a position in BMY as recently as Q1 2025.

SKBA Capital Management first reported a position in BMY in Q4 2020 and has held it in 16 quarters since. The position peaked at $285K in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • SKBA Capital Management held 3,700 shares of Bristol-Myers Squibb worth $224K as of Q1 2026.
  • Bristol-Myers Squibb was a new SKBA Capital Management position in Q1 2026.
  • Bristol-Myers Squibb made up 0.03% of SKBA Capital Management's portfolio in Q1 2026, its #79 holding.
  • SKBA Capital Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 16 quarters since.
  • SKBA Capital Management's Bristol-Myers Squibb position peaked at $285K in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on SKBA Capital Management's 13F filing for Q1 2026, filed 13 May 2026.